Amphastar Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Amphastar Pharmaceuticals, Inc. (AMPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -5.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -5.10%.
- Amphastar Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -3.20%.
- Amphastar Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -3.50%.
- Amphastar Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -0.20%, a 101.07% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -5.10% 10-K · filed 2026-02-26 | |
| 2023-12-31 | -3.20% 10-K · filed 2026-02-26 | |
| 2022-12-31 | -3.50% 10-K · filed 2025-03-03 | |
| 2021-12-31 | -0.20% 10-K · filed 2024-02-29 | |
| 2020-12-31 | 18.70% 10-K · filed 2023-03-01 | |
| 2019-12-31 | -1.50% 10-K · filed 2022-03-11 | |
| 2018-12-31 | 5.10% 10-K · filed 2021-03-15 | |
| 2017-12-31 | -166.20% 10-K · filed 2020-03-16 | -128.00% 10-K · filed 2018-03-14 |
| 2016-12-31 | 4.40% 10-K · filed 2019-03-15 | 3.00% 10-K · filed 2017-03-15 |
| 2015-12-31 | 7.70% 10-K · filed 2018-03-14 | |
| 2014-12-31 | 4.00% 10-K · filed 2017-03-15 | |
| 2013-12-31 | 6.30% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 4.00% 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |